Dupilumab for Aspirin-exacerbated Respiratory Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Aspirin-exacerbated Respiratory Disease

In brief

Subjects with physician-diagnosed aspirin-exacerbated respiratory disease (AERD) who remain unacceptably symptomatic with a SNOT 22 score \> 18 despite routine medical therapy will be enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in AERD.

Key facts

Study ID
NCT03595488
Run by
Rochester General Hospital
People needed
11
Starts
2018-09-05
Expected to finish
2019-12-11
Last updated by the study team
2020-08-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.